Yüklüyor......
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
About 25% of patients with acute myeloid leukemia (AML) harbor FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations and their prognosis remains poor. Gilteritinib is a FLT3 inhibitor approved by the US FDA for use in adult FLT3-mutated relapsed or refractory AML patients. Mo...
Kaydedildi:
| Yayımlandı: | Blood Cancer J |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8184771/ https://ncbi.nlm.nih.gov/pubmed/34099621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00502-7 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|